双靶点68Ga-NOTA-3P-TATE-RGD PET/CT在碘难治性分化型甲状腺癌中的探索性对比研究
双靶点显像总特异性优于18F-FDG(92.3% vs 70.6%),骨转移瘤/本底比值显著更高(3.4 vs 2.3,P=0.008),并在骨和脑转移中检出额外病灶;TERT启动子突变病灶对双靶点摄取最高,BRAF突变病灶对18F-FDG摄取最高。
要点
- 双靶点显像总特异性92.3%,高于18F-FDG的70.6%。
- 骨转移瘤/本底比值3.4 vs 2.3,P=0.008,双靶点显著更高。
- 双靶点独有病灶45个(12.71%),主要在骨(6个)和脑(5个)。
核心结论
- 68Ga-NOTA-3P-TATE-RGD PET/CT对放射性碘难治性DTC可行,与18F-FDG互补,增强骨和脑转移检出。
- TERT启动子突变病灶对该双靶点摄取最高,支持其用于特定疾病识别。
研究设计与样本
- 比较两种显像剂的诊断效能和半定量参数,并基于基因突变数据初步分析不同突变类型PET摄取差异。
主要发现
- 68Ga-NOTA-3P-TATE-RGD检出265个病灶,18F-FDG检出295个病灶。
- 双靶点独有病灶45个(12.71%),主要在骨(6个)和脑(5个);18F-FDG独有病灶75个,在淋巴结(24个)和肺(51个)。
- 双靶点总特异性92.3% vs 70.6%,骨转移瘤/本底比值3.4(2.6,4.0)vs 2.3(1.6,2.9),P=0.008。
- TERT启动子突变病灶双靶点摄取最高(P<0.01),BRAF突变病灶18F-FDG摄取最高(P<0.01)。
临床怎么用
- 对放射性碘难治性DTC,可考虑68Ga-NOTA-3P-TATE-RGD PET/CT与18F-FDG互补使用,尤其关注骨和脑转移。
- TERT启动子突变相关侵袭亚型可能从该双靶点显像中获益,支持特定疾病识别。
局限性
- 基因突变分析为初步分析,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This exploratory study aimed to evaluate the clinical feasibility and added diagnostic value of the heterodimeric agent 68 Ga-NOTA-3P-TATE-RGD, targeting both SSTR2 and integrin α v β 3 , in patients with radioactive-iodine-negative differentiated thyroid cancer (DTC), through a comparison with 18 F-FDG PET/CT. PATIENTS AND METHODS: Twenty-two patients with radioactive-iodine-negative DTC underwent both 68 Ga-NOTA-3P-TATE-RGD and 18 F-FDG PET/CT within 1 week. Diagnostic performance and semiquantitative parameters were compared between the two agents. Based on the collected gene mutation data, a preliminary analysis was conducted on differences in PET uptake among different gene mutation types. RESULTS: A total of 265 and 295 lesions were detected on 68 Ga-NOTA-3P-TATE-RGD and 18 F-FDG PET/CT, respectively. 68 Ga-NOTA-3P-TATE-RGD detected 45 exclusive lesions (12.71%), predominantly in bone (6 lesions) and brain (5 lesions), while 18 F-FDG identified 75 exclusive lesions in lymph nodes (24 lesions) and lungs (51 lesions). The dual-targeted agent exhibited superior total specificity (92.3% vs 70.6%) and significantly higher tumor-background ratio for bone metastases [3.4 (2.6, 4.0) vs 2.3 (1.6, 2.9), P = 0.008]. For PET comparison of different gene mutations, 68 Ga-NOTA-3P-TATE-RGD showed highest uptake in TERT promoter-mutant lesions ( P < 0.01), while 18 F-FDG had maximal uptake in BRAF-mutant lesions ( P < 0.01). CONCLUSIONS: 68 Ga-NOTA-3P-TATE-RGD PET/CT is feasible for radioactive-iodine-negative DTC, providing complementary diagnostic information to 18 F-FDG with enhanced detection of bone and brain metastases. The intense uptake observed in lesions with TERT-associated aggressive subtypes supports potential utility for specific disease identification.
引用
- Xiang J, Wang Y, Zhang X, et al. Dual-targeted 68 Ga-NOTA-3P-TATE-RGD PET/CT in Radioactive-iodine Negative Differentiated Thyroid Cancer : An Exploratory Comparative Study With 18 F-FDG. Clin Nucl Med. 2026. PMID: 41941241. doi:10.1097/RLU.0000000000006422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。